- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioLineRx Ltd (BLRX)
BioLineRx Ltd stock price live, this page displays NASDAQ BLRX stock exchange data. View the BLRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the BioLineRx Ltd real time stock price chart below.
What Is the BioLineRx Ltd Stock Price Today?
The BioLineRx Ltd stock price today is 2.240.
What Is the Stock Symbol for BioLineRx Ltd?
The stock symbol for BioLineRx Ltd is "BLRX."
What Stock Exchange Does BioLineRx Ltd Trade On?
BioLineRx Ltd is listed and trades on the NASDAQ stock exchange.
Is BioLineRx Ltd a Good Stock to Buy?
Determining whether BioLineRx Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLRX quote. (ISIN: US09071M3043)
What Is the BioLineRx Ltd Stock Price Today?
The BioLineRx Ltd stock price today is 2.240.
What Is the Stock Symbol for BioLineRx Ltd?
The stock symbol for BioLineRx Ltd is "BLRX."
What Stock Exchange Does BioLineRx Ltd Trade On?
BioLineRx Ltd is listed and trades on the NASDAQ stock exchange.
Is BioLineRx Ltd a Good Stock to Buy?
Determining whether BioLineRx Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLRX quote. (ISIN: US09071M3043)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.240
2.378
52 wk Range
2.150
7.770
BLRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.2402.378
52 wk Range
2.1507.770
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BLRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
17.500
Upside
+681.25%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 6K BioLineRx Ltd. For: 23 March
- Investing.com
- BioLineRx launches trial of brain cancer drug GLIX1
- Investing.com
- BioLineRx launches trial of brain cancer drug GLIX1
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BioLineRx Ltd Earnings Call Summary for Q4/2025
- BioLineRx reported 95.8% revenue decline to $1.2M in 2025, down from $28.9M in 2024, primarily due to absence of non-recurring license fees.
- Net loss improved 78.3% YoY to $2.0M from $9.2M, driven by reduced R&D expenses (down 12%) and G&A costs (down 50.8%).
- Stock fell 1.13% to $2.62 in premarket trading, near 52-week low of $2.30, despite analyst price targets ranging from $12-$26.
- Company maintains cash runway through mid-2027 with current ratio of 2.09, supported by potential APHEXDA royalties and milestone payments.
- Strategic focus shifts to GLIX1 cancer treatment entering glioblastoma clinical trials, targeting market with significant unmet medical needs.
Last Updated: 2026-03-23, 09:12 a/m
Read Full TranscriptCompare BLRX to Peers and Sector
Metrics to compare | BLRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.9x | −2.6x | −0.5x | |
PEG Ratio | −0.10 | −0.01 | 0.00 | |
Price/Book | 0.6x | 1.8x | 2.6x | |
Price / LTM Sales | 8.8x | 11.4x | 3.2x | |
Upside (Analyst Target) | - | 144.3% | 45.2% | |
Fair Value Upside | Unlock | 7.8% | 6.4% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.500
(+681.25% Upside)
Earnings
Latest Release
Mar 23, 2026
EPS / Forecast
-- / -0.08
Revenue / Forecast
194K / 5.61M
People Also Watch
FAQ
What Is the BioLineRx (BLRX) Stock Price Today?
The BioLineRx stock price today is 2.240 USD.
What Stock Exchange Does BioLineRx Trade On?
BioLineRx is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for BioLineRx?
The stock symbol for BioLineRx is "BLRX."
What Is the BioLineRx Market Cap?
As of today, BioLineRx market cap is 10.450M USD.
What Is BioLineRx's Earnings Per Share (TTM)?
The BioLineRx EPS (TTM) is -0.001.
When Is the Next BioLineRx Earnings Date?
BioLineRx will release its next earnings report on Nov 24, 2025.
From a Technical Analysis Perspective, Is BLRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has BioLineRx Stock Split?
BioLineRx has split 2 times.
How Many Employees Does BioLineRx Have?
BioLineRx has 22 employees.
What is the current trading status of BioLineRx (BLRX)?
As of Apr 23, 2026, BioLineRx (BLRX) is trading at a price of 2.240 USD, with a previous close of 2.240 USD. The stock has fluctuated within a day range of 2.240 USD to 2.378 USD, while its 52-week range spans from 2.150 USD to 7.770 USD.
What Is BioLineRx (BLRX) Price Target According to Analysts?
The average 12-month price target for BioLineRx is 17.500 USD, with a high estimate of 23 USD and a low estimate of 12 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +681.25% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.